No Data
No Data
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Cabaletta Bio to Participate in Upcoming Investor Conferences in September
Evercore ISI Cuts Price Target on Cabaletta Bio to $15 From $25, Keeps Outperform Rating
Several Headwinds Dragged Cabaletta Bio (CABA) in Q2
Wells Fargo Maintains Cabaletta Bio(CABA.US) With Buy Rating, Maintains Target Price $20
Buy Rating Affirmed for Cabaletta Bio Amid Superior CD19 CAR T Therapy Efficacy in Autoimmune Disease Treatment
No Data
No Data